Checkpoint immunotherapy utilizing PD-1 blockade has become the standard of care for metastatic melanoma. While this treatment is effective in 40 percent of patients, the other 60 percent develop resistance, leading to tumor regrowth. A multidisciplinary research team has identified a new strategy that could enhance the therapeutic effectiveness of this therapy by targeting the communication between immune cells within the tumor.